MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Anticholinergic medications"

  • 2025 International Congress

    Scopolamine-induced Tardive Dyskinesia: A Case Report

    H. Deville, M. Christie (Houston, USA)

    Objective: To present a case of scopolamine-related Tardive Dyskinesia (TD) and review the documented anticholinergic-associated cases of TD and the underlying pathophysiology responsible for TD.…
  • 2025 International Congress

    Trihexyphenidyl as a Treatment for Severe Freezing of Gait in Parkinson’s Disease: A Case Report

    J. Ha, M. Ferris (Palo Alto, USA)

    Objective: To present a unique case in which trihexyphenidyl was used as an effective treatment to dramatically reduce freezing of gait (FoG) in a Parkinson’s…
  • 2025 International Congress

    Association between cognitive adverse effects of anticholinergic medication and development of long-term dementia in Parkinson’s disease

    SH. Ha, BR. Jin, SY. Kim, SM. Lee, JH. Shin, HJ. Kim (Seoul, Republic of Korea)

    Objective: To investigate whether cognitive adverse effects occurring immediately after taking anticholinergics are related to the development of long-term dementia and to interpret this from…
  • 2024 International Congress

    Trihexyphenidyl Use in a Parkinsonian Phenotype of Gerstman-Sträussler-Scheinker Syndrome

    P. Atit, S. Aradi (Tampa, USA)

    Objective: To highlight clinical improvement in a patient with a parkinsonian presentation of Gerstmann-Sträussler-Scheinker (GSS) syndrome who was treated with trihexyphenidyl. Background: GSS is a…
  • 2023 International Congress

    Potentially inappropriate medication useage among patients newly diagnosed with dementia with Lewy bodies

    K. Wyman-Chick, E. Chrenka, M. Barrett, M. Miller, L. Sargent, J. Kuntz, H. Nguyen, A. Werner, Z. Libert, R. Rossom (St Paul, USA)

    Objective: Investigate the use of potentially inappropriate medications (PIM) among patients newly diagnosed with dementia with Lewy bodies (DLB). Background: PIM, including anticholinergics, are associated…
  • 2023 International Congress

    Association Between Anticholinergic Burden, MCI, and Cholinergic Denervation

    R. Paalanen, S. Roytman, P. Kanel, N. Bohnen (Ann Arbor, USA)

    Objective: To characterize the relationship between anticholinergic burden (ACB), mild cognitive impairment (MCI), and its underlying cholinergic pathology. Background: MCI is a common phenomenon in…
  • 2022 International Congress

    Hyperkinetic movement disorder following Covid: A Temporal corelation or Coincidental ?

    GP. Burman (Hisar, India)

    Objective: Hypokinetic movement disorder and parkinsonian like picture has been well described in literature but hyperkinetic movements are extremely rare and less highlighted in global…
  • 2022 International Congress

    Adult-onset axial dystonia: a rare condition that can lean on an early combined treatment approach

    P. Mitrotti, G. Vaghi, V. Grillo, C. Susca, R. de Icco, M. Allena, M. Avenali, C. Tassorelli (Pavia, Italy)

    Objective: To describe a rare case of adult-onset axial dystonia treated successfully with a  combined therapeutic approach. Background: Adult-onset truncal dystonia is an unusual condition…
  • 2022 International Congress

    Changes in anticholinergic burden in patients with Parkinson’s disease (PD) after bilateral deep brain stimulation (DBS) of the globus pallidus (GP) and subthalamic nucleus (STN)

    J. Jiao, M. Wilheimi, B. Brumbach, D. Safarpour (Portland, USA)

    Objective: To evaluate the effect of GP and STN DBS upon anticholinergic medication burden in patients with PD. Background: Medications with anticholinergic effects are commonly…
  • MDS Virtual Congress 2021

    Low dose trihexyphenidyl use causes cognitive dysfunction in Parkinson’s disease patients.

    L. Popil, M. Gavriliuc, A. Andrusca, O. Gavriliuc (Chisinau, Republic of Moldova)

    Objective: Evaluate cognitive performance in Parkinson's disease patients receiving a low dose of trihexyphenidyl (THP). Background: Before L-Dopa's discovery, anticholinergic drugs were among the first…
  • 1
  • 2
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley